



5th Swedish Medicinal Chemistry Symposium

22-23 April, 2026, Stockholm, Sweden

Program

Wednesday 22 April	
09.45 – 10.00	Opening remarks – House keeping Chair: Lena Ripa, AstraZeneca
10.00 – 10.30	AP3-Driven Discovery of ACR-2316, a Dual WEE1/PKMYT1 Inhibitor with Superior Single-Agent Activity Caroline Wigerup, Acrivon Therapeutics
10.30 – 11.00	DNA-Encoded Libraries as a Hit Discovery Tool: Insights from the SciLifeLab DDD platform Johan Wannberg, SciLifeLab
11.00 – 11.30	Phenotypic screening towards the next generation antivirals Mikael Elofsson, Umeå University
11.30 – 12.00	Discovery of AZD6793, a highly potent and selective IRAK4 inhibitor in clinical development for the treatment of COPD Ina Terstiege, AstraZeneca
12.00 – 13.30	Lunch & Networking Chair: Ulf Nilsson, Lund University
13.30 – 14.00	Challenging the importance of chameleonicity for oral absorption of PROTACs Jenny Viklund, AstraZeneca
14.00 – 14.30	Programmable Skeletal Editing for Rapid Construction of sp³-Rich Scaffolds Sebastian Clementson, Lund University
14.30 – 15.00	One ring to rule all hallmarks of cancer – Discovery of combined galectin-1 and -3 inhibitors Fredrik Zetterberg, Biozet
15.00 – 15.45	Coffee break – Poster session
15.45 – 16.15	Chemical switching: Giving new functions to DNA damage repair enzymes Alice Eddershaw, Karolinska Institutet
16.15 – 16.45	Synthesis of a duocarmycin like enzymatically activated prodrug Christoffer Bengtsson, SciLifeLab
16.45 – 17.15	Discovery of Pirepemat, for the Prevention of Falls in Parkinson's Disease, Using Phenotypic In Vivo Screening Henrik Gradén, Integrative Research Laboratories Sweden
17.15 – 18.15	Refreshments & Poster session
18.15 – 20.30	Casual dinner



5th Swedish Medicinal Chemistry Symposium

22-23 April, 2026, Stockholm, Sweden

Program

Thursday 23 April	
09.00 – 09.15	House keeping – The Swedish Pharmaceutical Society 2026 Medicinal Chemistry Award Chair: Anders Karlén, Uppsala University
09.15 – 10.00	Award lecture – The Swedish Pharmaceutical Society 2026 Medicinal Chemistry Award
10.00 – 10.45	Coffee break – Poster session
10.45 – 12.00	Short presentations selected from poster abstracts 15 minutes each
12.00 – 13.30	Lunch & Networking Chair: Katarina Färnegårdh, Xspray Pharma
13.30 – 14.00	Discovery and development of GRK2-biased b2-adrenergic receptor agonists for the treatment of metabolic disorders Benjamin Pelcman, Atrogi
14.00 – 14.30	Title to be announced Annette Bayer, The Arctic University of Norway Tromsø
14.30 – 15.00	Targeted Protein Degradation Through Modification Strategies Jonas Malmström, Ofichem Uppsala
15.00 – 15.30	Discovery and Optimization of a Potent Bicyclic Peptide Molecule Inhibiting NPR3 for the Treatment of Chronic kidney diseases Anais Noisier, AstraZeneca
15.30 – 15.45	Poster award
15.45 – 16.00	Concluding remark – End of Meeting